Understanding the SHIVERS Programme: A Cornerstone of Influenza Surveillance
The Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance (SHIVERS) programme stands as a pioneering effort in global public health, spearheaded from New Zealand. Launched in 2012, this multi-phase initiative has tracked influenza and other respiratory viruses across thousands of participants, blending hospital surveillance, community cohorts, and genomic analysis to paint a comprehensive picture of viral dynamics. Hosted primarily at PHF Science—formerly the Institute of Environmental Science and Research (ESR)—SHIVERS has amassed over $62 million in international funding, with its latest phase, SHIVERS-VI, extending research through 2029.
What sets SHIVERS apart is its holistic approach: unlike conventional systems that focus solely on severe cases, it captures mild illnesses too, revealing the true burden of diseases like influenza. This methodology has not only informed New Zealand's policies but also rippled outward, influencing World Health Organization (WHO) guidelines and vaccine strategies worldwide. For researchers in New Zealand's universities, such as the University of Auckland and University of Otago, SHIVERS represents a goldmine of data-driven opportunities in virology and epidemiology.
New Zealand Universities at the Heart of SHIVERS Innovation
New Zealand's higher education institutions have been integral to SHIVERS' success. The University of Auckland led SHIVERS-V, a phase examining the effects of COVID-19 border restrictions on respiratory viruses, in partnership with PHF Science and the Immunization Advisory Centre. This collaboration secured significant funding, including an $8.3 million grant for the related Triple R programme aimed at predicting and mitigating flu risks, particularly for Māori and Pacific communities.
Meanwhile, University of Otago researchers have contributed key publications analyzing SHIVERS data, such as comparisons of COVID-19 and influenza incidence rates from SHIVERS-II, III, and IV cohorts. These academic outputs underscore how university-based teams drive real-world impact, from seroepidemiology to spatial transmission modeling. Aspiring academics can find parallel opportunities via platforms like higher ed research jobs or university jobs in New Zealand.
Way 1: Revolutionizing Childhood Vaccination Policies
SHIVERS-I data exposed alarmingly high hospitalization rates among young children with low vaccination coverage, prompting a landmark policy shift. In 2013, New Zealand made flu vaccines free for children under five with prior respiratory hospitalizations or significant illness history. This change, directly informed by the programme's findings, boosted protection for high-risk groups and serves as a model for equity-focused immunization.
Way 2: Aligning Global Surveillance Standards
Early SHIVERS surveillance revealed that influenza positives persisted up to 9 days post-symptom onset, challenging the prior 7-day WHO threshold. This led to a 2014 update extending it to 10 days, standardizing practices across 194 countries. Enhanced comparability now bolsters pandemic monitoring, a boon for international collaborations involving NZ academics.
Way 3: Shaping WHO's Pandemic Severity Framework
SHIVERS-I's robust metrics on transmissibility, severity, and healthcare strain fed into WHO's Global Pandemic Influenza Severity Assessment framework. By quantifying these elements, the programme equips decision-makers with evidence for timely responses, highlighting the value of longitudinal data from Southern Hemisphere sentinels like New Zealand.
Way 4: Building New Zealand's Respiratory Surveillance Infrastructure
The programme birthed a national platform for respiratory diseases, now Ministry of Health-funded and shared globally. This infrastructure proved vital during COVID-19, tracking weekly data to guide lockdowns and vaccinations. University researchers leverage it for studies on everything from RSV dynamics to avian flu threats.
Photo by Duskfall Crew on Unsplash
Way 5: Paving the Path to Universal Flu Vaccines
A 2015 SHIVERS discovery showed higher anti-neuraminidase (NA) antibodies than anti-hemagglutinin (HA) levels, sparking US trials for broader vaccines incorporating NA. This could yield longer-lasting protection, transforming annual shots into decade-spanning solutions—a testament to NZ-led innovation influencing global pharma.
Way 6: Proving Efficacy of Public Health Measures
SHIVERS-II, III, and IV cohorts captured New Zealand's 2020-2021 flu absence amid lockdowns and borders, quantifying transmission drops for flu and RSV. This real-world evidence validated non-pharmaceutical interventions, informing post-pandemic strategies worldwide.
Way 7: Demonstrating COVID-19 Vaccine Impact on Transmission
Longitudinal tracking showed high effectiveness in curbing community spread, guiding equitable rollouts and communications. These insights from Wellington cohorts continue to shape booster policies and hybrid threat preparedness.
SHIVERS-VI: Charting Immunity Gaps and Future Threats
The newest phase, funded by $12 million from the US, probes the two-year flu hiatus's immunity implications using 15 years of data. Led by Prof. Sue Huang, it positions NZ as a 'unique laboratory' for viruses, with university partners analyzing genomic shifts in strains like H5N1. For virologists, this opens doors in postdoc positions and research jobs.
Implications for Higher Education and Research Careers in NZ
SHIVERS exemplifies how university-public sector partnerships amplify impact. Publications from Otago and Auckland have advanced fields like immune response modeling, attracting grants and talent. Early-career researchers benefit from hands-on cohort studies, preparing them for global roles. Check academic CV tips or free resume templates to join such teams.
- Collaborative funding opportunities via Flu Lab and NIAID.
- Access to longitudinal datasets for theses and papers.
- Training in genomic surveillance and serology.
Broader Global and Local Impacts
Beyond flu, SHIVERS data informs RSV, COVID, and emerging viruses, fostering resilient health systems. In NZ, it addresses inequities, aligning with higher ed's mission to serve diverse populations. Future outlooks include AI-enhanced predictions, inviting interdisciplinary talent from maths to medicine.
Photo by Bill Fairs on Unsplash
Opportunities and Calls to Action for Academics
As SHIVERS evolves, NZ universities seek experts in infectious diseases. Explore higher ed jobs, rate your professors, or career advice to advance your path. Engage with ongoing studies to contribute to virus management worldwide.